R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 1/5/20

4 weeks ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

This week, Covid-19 vaccines see some advancement, with remdesivir showing strong signs of success as Pfizer prepare to put their own candidate through U.S. trials starting from next week. In other news, ‘natural killer’ cell therapies show strong potential efficacy in fighting cancers as the next big cell therapy, and GSK announces that almost all non-Covid-related drug trials have been delayed in its search for a Covid vaccine.

PHASE 3 REMDESIVIR TRIAL SHOWS PROMISING SIGNS OF SUCCESS – Gilead’s antiviral drug Remdesivir has shortened the average recovery time for Covid-19 in the largest of several recent trials. Weak evidence also shows that the drug reduces death in patients. The U.S. director of NIAID hailed the drug as the ‘standard of care’. It allegedly reduced average time to recover by 31% over those taking a placebo. This comes as five hospitals in Australia are set to receive doses of the sought-after drug. The only confirmed hospital so far is St Vincent’s hospital in Sydney. 

PFIZER PREPARING FOR U.S. COVID-19 TRIALS NEXT WEEK – Pfizer will begin clinical trials of mRNA-based Covid candidate BNT162 in America next week, the company announced. The product has already undergone phase 1 and 2 trials in Germany, with FDA approval expected ‘shortly’. The company is expecting to manufacture millions of doses of the drug by the end of 2020.

HIGH-DOSE CHLOROQUINE TRIAL STOPPED OVER RAISED DANGER OF DEATH – A study of chloroquine, a drug similar to anti-malaria treatment hydroxychloroquine, has been stopped after high-dose patients showed a higher death rate than those who took low doses of the drug. High-dose patients also showed higher incidences of toxicity, though elements of the study meant researchers could not determine the independent toxicity of high-dose chloroquine. 

In other news: 

R&D

Natural killer cell therapies show promise for fighting cancer

Clinical Trials

GSK has delayed most of its non-Covid-19 clinical trials

UK’s ACCORD-2 pharma collaboration looks to cut Covid-19 drug development to a few weeks

AiCure releases ‘digital biomarker’ app for clinical trials

Manufacturing

AstraZeneca partners with Oxford University to produce potential vaccine

J&J and Catalent sign deal over Covid-19 vaccine manufacturing

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

Weekly News Round-up – 22/5/20

Big news this week, with AstraZeneca potentially ready to produce a Covid-19 vaccine by September this year, and Moderna receiving good news about its early-stage human trials for the same thing. In other news, the Trump administration’s new manufacturing partner...

7 days ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 22/5/20

Big news this week, with AstraZeneca potentially ready to produce a Covid-19 vaccine by September this year, and Moderna receiving good news about its early-stage human trials for the same thing. In other news, the Trump administration’s new manufacturing partner...

7 days ago

Weekly News Round-up – 15/5/20

In the news this week, remdesivir is authorised for emergency use in COVID-19. The drug has still not been proven to increase survival rates, but it will be vital to reduce patient recovery times. In other news, Takeda announces surprise...

2 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 15/5/20

In the news this week, remdesivir is authorised for emergency use in COVID-19. The drug has still not been proven to increase survival rates, but it will be vital to reduce patient recovery times. In other news, Takeda announces surprise...

2 weeks ago

The Rise of Independent Clinical Trial Sites

When looking for the right trial site for their study, clinical sponsors need a number of specific measures and conditions that will ensure greatest value for them. Enrolling requirements must be met, but more importantly the most rigorous safety and quality...

2 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

The Rise of Independent Clinical Trial Sites

When looking for the right trial site for their study, clinical sponsors need a number of specific measures and conditions that will ensure greatest value for them. Enrolling requirements must be met, but more importantly the most rigorous safety and quality...

2 weeks ago
Working With us

Interested?
Reserve your space